Halozyme Therapeutics, Inc. (NASDAQ:HALO) Analyst Ratings as of May 17, 2018

May 17, 2018 - By Rebecca Betts

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Corporate Logo
Big Money Sentiment increased to 1.66 in 2017 Q4. It has change of 0.40, from 2017Q3’s 1.26. The ratio is positive due to Halozyme Therapeutics, Inc. positioning: 13 sold and 45 reduced. 39 funds acquired stakes and 57 increased stakes. Investors holded 118.53 million in 2017Q3 but now own 118.31 million shares or 0.18% less.
Aqr Management Limited Liability stated it has 0% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Adage Prns Gp Limited Liability Com invested in 0.01% or 250,000 shs. Northern Corp accumulated 0.01% or 1.65M shs. Millennium Mgmt stated it has 0.04% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Hbk L P has invested 0.01% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Alliancebernstein L P reported 271,654 shs. Us Retail Bank De owns 4,045 shs. Amer Intl Inc has 80,389 shs. Fred Alger Mngmt reported 0.04% of its capital in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Pictet Asset Mngmt Limited invested in 2.45M shs. Fny Managed Accounts Ltd Co holds 0% or 164 shs in its capital. Brown Advisory Inc reported 0.01% stake. Wells Fargo And Mn invested in 0% or 311,282 shs. Weiss Asset Mngmt Ltd Partnership owns 20,814 shs. Credit Suisse Ag reported 123,772 shs.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Ratings Coverage

Total analysts of 6 have positions in Halozyme (NASDAQ:HALO) as follows: 3 rated it a “Buy”, 1 with “Sell” and 2 with “Hold”. The positive are 50%. Since November 22, 2017 according to StockzIntelligence Inc Halozyme has 9 analyst reports. The stock rating was downgraded by Barclays Capital to “Underweight” on Friday, May 11. On Wednesday, January 24 the firm has “Buy” rating given by Deutsche Bank. On Thursday, February 22 the company was maintained by BMO Capital Markets. On Wednesday, February 21 JP Morgan maintained the shares of HALO in report with “Overweight” rating. On Wednesday, November 22 the stock of Halozyme Therapeutics, Inc. (NASDAQ:HALO) has “Hold” rating given by Barclays Capital. On Wednesday, February 21 Canaccord Genuity maintained Halozyme Therapeutics, Inc. (NASDAQ:HALO) rating. Canaccord Genuity has “Buy” rating and $21.0 target. On Monday, May 14 the rating was maintained by Canaccord Genuity with “Buy”. Listed here are Halozyme Therapeutics, Inc. (NASDAQ:HALO) PTs and latest ratings.

14/05/2018 Broker: Canaccord Genuity Rating: Buy New Target: $21.0000 Maintain
11/05/2018 Broker: Barclays Capital Old Rating: Equal-Weight New Rating: Underweight Old Target: $19 Downgrade
22/02/2018 Broker: BMO Capital Markets Old Rating: Market Perform New Rating: Market Perform Old Target: $18 New Target: $19 Maintain
21/02/2018 Broker: Canaccord Genuity Rating: Buy New Target: $21.0 Maintain
21/02/2018 Broker: JP Morgan Old Rating: Overweight New Rating: Overweight Old Target: $19 New Target: $22 Maintain
24/01/2018 Broker: Deutsche Bank Rating: Buy New Target: $21.0 Maintain
24/01/2018 Broker: Goldman Sachs Rating: Neutral New Target: $20 Initiates Coverage On
17/01/2018 Broker: BMO Capital Markets Rating: Hold New Target: $18.0
22/11/2017 Broker: Barclays Capital Rating: Hold New Target: $19.0 Downgrade

Ticker’s shares touched $18.16 during the last trading session after 2.47% change.Currently Halozyme Therapeutics, Inc. is uptrending after 32.10% change in last May 17, 2017. HALO has also 644,666 shares volume. The stock outperformed the S&P500 by 20.55%.

Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally.The firm is valued at $2.60 billion. The companyÂ’s human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.The P/E ratio is 40.36. The Company’s products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

More recent Halozyme Therapeutics, Inc. (NASDAQ:HALO) news were posted by Benzinga.com, Benzinga.com and Seekingalpha.com. The first one has “22 Stocks Moving In Friday’s Pre-Market Session” as a title and was posted on May 11, 2018. The next is “38 Stocks Moving In Friday’s Mid-Day Session” on May 11, 2018. And last was posted on May 11, 2018, called “Premarket analyst action – healthcare”.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.